Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

Springer Science and Business Media LLC - Tập 5 Số 1 - 2020
Euy Sung Moon1, Filipe Elvas2, Gwendolyn Vliegen3, Stef De Lombaerde2, Christel Vangestel2, Sven De Bruycker4, An Bracke3, Elisabeth Eppard5, Lukas Greifenstein1, Benedikt Klasen1, Vasko Kramer5, Steven Staelens4, Ingrid De Meester3, Pieter Van der Veken3, Frank Rösch1
1Department of Chemistry – TRIGA Site, Johannes Gutenberg University Mainz, 55128, Mainz, Germany
2Department of Nuclear Medicine, Antwerp University Hospital (UZA), 2650, Edegem, Belgium
3Department of Pharmaceutical Sciences, Laboratory of Medical Biochemistry, University of Antwerp, 2610, Wilrijk, Belgium
4Molecular Imaging Center Antwerp (MICA), University of Antwerp, 2610, Wilrijk, Belgium
5Positronpharma SA, 7500921, Providencia, Santiago, Chile

Tóm tắt

Abstract Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid (SA) containing bifunctional DATA5m and DOTA chelators based on UAMC1110 as pharmacophor. The novel radiopharmaceuticals DOTA.SA.FAPi and DATA5m.SA.FAPi with their non-radioactive derivatives were characterized for in vitro inhibitory efficiency to FAP and PREP, respectively and radiochemical investigated with gallium-68. Further, first proof-of-concept in vivo animal study followed by ex vivo biodistribution were determined with [68Ga]Ga-DOTA.SA.FAPi. Results [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DATA5m.SA.FAPi showed high complexation > 97% radiochemical yields after already 10 min and high stability over a period of 2 h. Affinity to FAP of DOTA.SA.FAPi and DATA5m.SA.FAPi and its natGa and natLu-labeled derivatives were excellent resulting in low nanomolar IC50 values of 0.7–1.4 nM. Additionally, all five compounds showed low affinity for the related protease PREP (high IC50 with 1.7–8.7 μM). First proof-of-principle in vivo PET-imaging animal studies of the [68Ga]Ga-DOTA.SA.FAPi precursor in a HT-29 human colorectal cancer xenograft mouse model indicated promising results with high accumulation in tumor (SUVmean of 0.75) and low background signal. Ex vivo biodistribution showed highest uptake in tumor (5.2%ID/g) at 60 min post injection with overall low uptake in healthy tissues. Conclusion In this work, novel PET radiotracers targeting fibroblast activation protein were synthesized and biochemically investigated. Critical substructures of the novel compounds are a squaramide linker unit derived from the basic motif of squaric acid, DOTA and DATA5m bifunctional chelators and a FAP-targeting moiety. In conclusion, these new FAP-ligands appear promising, both for further research and development as well as for first human application.

Từ khóa


Tài liệu tham khảo

Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α. J Biol Chem. 2005;280(20):19441–4.

Bracke A, Van Elzen R, Van Der Veken P, Augustyns K, De Meester I, Lambeir AM. The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma. Clin Chim Acta. 2019;495(April):154–60 Elsevier.

Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11(2):257–66.

Busek P, Mateu R, Zubal M, Kotackova L, Sedo A. Targeting fibroblast activation protein in cancer - prospects and caveats. Front Biosci - Landmark. 2018;23(10):1933–68.

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. Springer US. 2019;18(2):99–115.

Cheng JD, Dunbrack RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002;62(16):4767–72.

Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem. 2008;51(19):6005–13.

De Decker A, Vliegen G, Van Rompaey D, Peeraer A, Bracke A, Verckist L, et al. Novel small molecule-derived, highly selective substrates for fibroblast activation protein (FAP). ACS Med Chem Lett. 2019;10(8):1173–9.

De Vlieghere E, Verset L, Demetter P, Bracke M, De Wever O. Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics. Virchows Arch. 2015;467(4):367–82.

Dvořáková P, Bušek P, Knedlík T, Schimer J, Etrych T, Kostka L, et al. Inhibitor-decorated polymer conjugates targeting fibroblast activation protein. J Med Chem. 2017;60(20):8385–93.

Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem. 2006;281(11):7437–44.

Eppard E, Wuttke M, Nicodemus PL, Rösch F. Ethanol-based post-processing of generator-derived 68Ga toward kit-type preparation of 68Ga-radiopharmaceuticals. J Nucl Med. 2014;55(6):1023–8.

Giesel FL, Heussel CP, Lindner T, Röhrich M, Rathke H, Kauczor HU, et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging. 2019a;46(8):1754–5.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019b;60(3):386–92.

Greifenstein L, Engelbogen N, Lahnif H, Sinnes J-P, Bergmann R, Bachmann M, et al. Synthesis, labeling and preclinical evaluation of a squaric acid containing PSMA-inhibitor labeled with 68Ga – a comparison with PSMA-11 and PSMA-617. ChemMedChem. 2020;15(8):695–704. https://doi.org/10.1002/cmdc.201900559.

Greifenstein L, Grus T, Nagel J, Sinnes JP, Rösch F. Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA5 for versatile labeling with 44Sc, 64Cu, 68Ga and 177Lu. Appl Radiat Isot. Elsevier Ltd. 2019;108867.

Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics - Clin Appl. 2014;8(5–6):454–63.

Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736–41.

Ian Storer R, Aciro C, Jones LH. Squaramides: physical properties, synthesis and applications. Chem Soc Rev. 2011;40(5):2330–46.

Jansen K, De Winter H, Heirbaut L, Cheng JD, Joossens J, Lambeir AM, et al. Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold. Medchemcomm. 2014b;5(11):1700–7.

Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J Med Chem. 2014a;57(7):3053–74.

Jiang G-M, Xu W, Du J, Zhang K-S, Zhang Q-G, Wang X-W, et al. The application of the fibroblast activation protein alpha-targeted immunotherapy strategy. Oncotarget. 2016;7(22):33472-82. https://doi.org/10.18632/oncotarget.8098.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5.

Kreppel B, Gärtner F, Marinova M, Attenberger U, Meisenheimer M, Toma M, et al. [68Ga]Ga-DATA5m.SA .FAPi PET/CT: Specific tracer-uptake in focal nodular hyperplasia and potential role in liver tumor imaging. Nuklearmedizin. 2020:8–10. https://doi.org/10.1055/a-1164-5667, https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1164-5667.

Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Muller E, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29(6):1768–78.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22.

Liu R, Li H, Liu L, Yu J, Ren X. Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther. 2012;13(3):123–9.

Liu T, Zhou L, Li D, Andl T, Zhang Y. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol. 2019;7(APR):1–14.

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421–9.

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jaeger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423–9.

Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505–12.

Poplawski SE, Lai JH, Li Y, Jin Z, Liu Y, Wu W, et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013;56(9):3467–77.

Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43(1):260–90.

Quiñonero D, Frontera A, Ballester P, Deyà PM. A theoretical study of aromaticity in squaramide and oxocarbons. Tetrahedron Lett. 2000;41(12):2001–5.

Rudd SE, Roselt P, Cullinane C, Hicks RJ, Donnelly PS. A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies. Chem Commun Royal Soc Chem. 2016;52(80):11889–92.

Scanlan MJ, Raj BKM, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994;91(12):5657–61.

Seemann J, Waldron B, Parker D, Roesch F. DATATOC: a novel conjugate for kit-type 68Ga labelling of TOC at ambient temperature. EJNMMI Radiopharm Chem. 2017;1(1) http://www.ejnmmipharmchem.springeropen.com/content/1/1/4.

Seemann J, Waldron BP, Roesch F, Parker D. Approaching “kit-type” labelling with 68Ga: the DATA chelators. ChemMedChem. 2015;10(6):1019–26.

Sinnes JP, Nagel J, Waldron BP, Maina T, Nock BA, Bergmann RK, et al. Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC. EJNMMI Res. 2019;9. https://doi.org/10.1186/s13550-019-0516-7, https://ejnmmires.springeropen.com/articles/10.1186/s13550-019-0516-7.

Tao L, Huang G, Song H, Chen Y, Chen L. Cancer associated fibroblasts: an essential role in the tumor microenvironment (review). Oncol Lett. 2017;14(3):2611–20.

Tietze LF, Arlt M, Beller M, Glüsenkamp K-H, Jähde E, Rajewsky MF. Squaric acid diethyl ester: a new coupling reagent for the formation of drug biopolymer conjugates. Synthesis of squaric acid ester amides and diamides. Chem Ber. 1991;124(5):1215–21.

Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, et al. Theranostics targeting fibroblast activation protein in the tumor Stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer Xenograft mouse models. J Nucl Med. 2020;61(4):563–9.

Wurm FR, Klok HA. Be squared: expanding the horizon of squaric acid-mediated conjugations. Chem Soc Rev. 2013;42(21):8220–36.

Yang X, Nimmagadda S, Rowe S, Slania S, Pomper MG. Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha). Patent, 2019.

Yoganathan S, Sit CS, Vederas JC. Chemical synthesis and biological evaluation of gallidermin-siderophore conjugates. Org Biomol Chem. 2011;9(7):2133–41.

Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review). Mol Med Rep. 2015;11(5):3203–11.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 5 Số 1

Thông tin tác giả